Cancer

Bruin CLL 321

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated CLL/Small Lymphocytic Lymphoma

Trial overview

Disease

Haematology

Topic

Bruin CLL 321

Sponsor

Description

This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have previously received treatment with at least a BTK inhibitor. The main purpose is to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab. Participation could last up to four years, and possibly longer, if the disease does not progress

Study details

For detailed information on this trial, please click here

Trial status

Actively recruiting

Location

Principle Investigator

Professor George Follows

MA, BM BCh (Oxon), PhD, FRCP, FRCPath

Consultant haematologist